PET‐adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: results of the GATLA LH‐05 trial
- 12 March 2019
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 185 (5) , 865-873
Abstract
Summary: The role of Ann Arbor staging in determining treatment intensity after achieving a negative positron emission tomography (PET) has not been established in classical Hodgkin lymphoma (cHL). Patients with stage I–IV cHL, received three cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) and an interim PET scan (PET3). PET3‐negative patients received no further therapy. PET3‐positive patients received three additional cycles of ABVD plus involved‐field radiation therapy or salvage chemotherapy, if refractory to ABVD, and were re‐evaluated by PET scan (PET6). Study endpoints were 3‐year progression‐free survival (PFS) and overall survival (OS) rates. Two hundred and thirty‐nine patients with early‐stage and 138 with advanced‐stage were evaluable. Overall, 260 patients (70%) were PET3‐negative and had higher 3‐year PFS (90% vs. 65%; P < 0·0001) and OS (98% vs. 92%; P = 0·007) rates than PET3‐positive patients. All PET3‐negative patients, regardless of disease stage at diagnosis, achieved similarly good PFS (90–91%; P = 0·76) and OS (97–99%). The only independent prognostic factor for PFS was PET3‐negativity (Hazard ratio 3·8; 95% confidence interval 2·4–6·3; P < 0·0001). This study suggests that cHL patients who achieve a negative PET3 following ABVD have an excellent outcome, regardless of stage at diagnosis. An appropriately powered, phase III trial will be necessary to confirm these findings.Keywords
This publication has 17 references indexed in Scilit:
- Interim Positron Emission Tomography Response–Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 StudyJournal of Clinical Oncology, 2016
- Second Cancer Risk Up to 40 Years after Treatment for Hodgkin’s LymphomaNew England Journal of Medicine, 2015
- Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s LymphomaNew England Journal of Medicine, 2015
- Omitting Radiotherapy in Early Positron Emission Tomography–Negative Stage I/II Hodgkin Lymphoma Is Associated With an Increased Risk of Early Relapse: Clinical Results of the Preplanned Interim Analysis of the Randomized EORTC/LYSA/FIL H10 TrialJournal of Clinical Oncology, 2014
- Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496)Journal of Clinical Oncology, 2013
- Risk-Adapted Therapy With Three or Six Cycles of Doxorubicin/Bleomycin/Vinblastine/Dacarbazine Plus Involved-Field Radiation Therapy in Hodgkin Lymphoma, Based on Prognosis at Diagnosis and Early Response: Results From the GATLA StudyClinical Lymphoma Myeloma and Leukemia, 2010
- Report on the First International Workshop on interim-PET scan in lymphomaLeukemia & Lymphoma, 2009
- Early Interim 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish StudyJournal of Clinical Oncology, 2007
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- Long-Term Cause-Specific Mortality of Patients Treated for Hodgkin’s DiseaseJournal of Clinical Oncology, 2003